SOMETHING IS ROTTEN IN THE STATE OF NASH INDUCED FIBROSIS TRIALS


update-1672385 1280


UPDATE

GILEAD Confirmed yesterday (23th jan 2019)  that their intermediate results publications will be maintained in H1 2019, the update of clinicaltrial.gov records were supposed to modify only the final date of  the trial. 


In the last three weeks, one of the leading NASH induced fibrosis trials delayed the publication of its intermediates results.

Two weeks ago it was TOBIRA (Allergan) who delayed their results of AURORA (cenicriviroc trial)  by 14 months, and the 21 of january , we were surprised that GILEAD delayed ( on clinical trial.gov) the date of the completion of  intermediate results in STELLAR 3 and STELLAR 4.

According to the modifications published in clinicaltrial.gov records   STELLAR4 and STELLAR 3 did not intended to publish intermediates results anymore  but following this article, Gilead published a statement explaining the modifications and confirming the publication of intermediate results in H1 2019. 

So, to date, only three compounds are still in the race for 2019.

SELONSERTIB, OCALIVA and ELAFIBRANOR



G Divry 2019

Notice that I am neither a physician nor a biologist or financial analyst, my point of view is only that of an enlightened amateur, so it must be taken for what it is, a questionable point of view


The market forecast is now available including the new data’s





Share on StockTwits

WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE